Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Aethlon Medical ( (AEMD) ) just unveiled an update.
On October 14, 2025, Aethlon Medical, Inc. filed a Certificate of Change in Nevada to authorize a 1-for-10 reverse stock split of its common stock, effective October 16, 2025. This move is part of the company’s strategy to manage dilution and comply with Nasdaq listing requirements. The reverse stock split will adjust the number of shares outstanding and the CUSIP number, but will not affect the rights and privileges of shareholders or require stockholder approval.
The most recent analyst rating on (AEMD) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Aethlon Medical stock, see the AEMD Stock Forecast page.
Spark’s Take on AEMD Stock
According to Spark, TipRanks’ AI Analyst, AEMD is a Underperform.
Aethlon Medical’s overall stock score is low due to significant financial challenges, including persistent losses and cash flow issues. The technical indicators suggest negative momentum, and the valuation is unattractive given the negative P/E ratio and lack of dividends. While the earnings call presented some positive strategic efforts, such as cost reduction and trial advancements, the hurdles in clinical trials and financial constraints weigh heavily on the stock’s outlook.
To see Spark’s full report on AEMD stock, click here.
More about Aethlon Medical
Aethlon Medical, Inc. is a Nevada-based company operating in the medical industry, focusing on capital-markets and operational strategies.
Average Trading Volume: 3,005,429
Technical Sentiment Signal: Sell
Current Market Cap: $1.82M
For detailed information about AEMD stock, go to TipRanks’ Stock Analysis page.